MK-5172A

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Hepatitis CHepatitis C

Phase 2

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

CompletedNCT02115321

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2014-05-09End: 2015-06-16Updated: 2019-06-26

Phase 4

Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

WithdrawnNCT03143998

Merck Sharp & Dohme LLCHepatitis C

Start: 2018-02-12End: 2019-01-12Updated: 2017-11-09

Related Papers

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study

Clinical and Translational Gastroenterology2019-03-2814 citations

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

2018-01-1736 citations